COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF

1 .- 30 . (canceled)

31 . A compound of Formula (II-h):

or a pharmaceutically acceptable salt or isotopically labeled compound thereof,

wherein:

Y is phenyl substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 ;

R 1 is —(CH 2 ) n —(3- to 8-membered heterocycloalkyl) wherein:

the heterocycloalkyl is optionally substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 ,

n is 0, and

the 3- to 8-membered heterocycloalkyl is tetrahydrofuranyl;

each R 2a is hydrogen;

R 4 is a bond; and

R 5 is hydrogen or C 1 -C 6 alkyl.

32 . The compound of claim 31 , or a pharmaceutically acceptable salt, isotopically labeled compound, or stereoisomer thereof, wherein R 5 is hydrogen.

33 . The compound of claim 31 , or a pharmaceutically acceptable salt or isotopically labeled compound thereof, wherein Y is phenyl substituted with two substituents.

34 . The compound of claim 31 , or a pharmaceutically acceptable salt or isotopically labeled compound thereof, wherein Y is:

35 . The compound of claim 31 , or a pharmaceutically acceptable salt or isotopically labeled compound thereof, wherein Y is:

36 . The compound of claim 31 , or a pharmaceutically acceptable salt, isotopically labeled compound, or stereoisomer thereof, wherein R 1 is —(CH 2 ) n -(3- to 8-membered heterocycloalkyl) and the heterocycloalkyl is substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 .

37 . The compound of claim 31 selected from the group consisting of:

or a pharmaceutically acceptable salt or isotopically labeled compound of any of the foregoing.

38 . The compound of claim 31 selected from the group consisting of:

or a pharmaceutically acceptable salt or isotopically labeled compound of any of the foregoing.

39 . A pharmaceutical composition comprising the compound of claim 31 , or a pharmaceutically acceptable salt or isotopically labeled compound thereof, and one or more pharmaceutically acceptable carriers or excipients.

40 . A method of treating disease or disorder by inhibiting NLRP3 activity in a subject, the method comprising administering to the subject a compound of claim 31 , or a pharmaceutically acceptable salt or isotopically labeled compound thereof.

41 . The method of claim 40 , wherein disease or disorder is inflammation, a disease or disorder of the central nervous system, a skin disease, a rheumatic disease, or a cryopyrin-associated autoinflammatory syndrome.

42 . The method of claim 41 , wherein the disease or disorder is inflammation.

43 . The method of claim 41 , wherein the disease or disorder of the central nervous system is Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis.

44 . The method of claim 41 , wherein the skin disease is hidradenitis suppurativa.

45 . The method of claim 41 , wherein the rheumatic disease is Still's disease.

46 . The method of claim 41 , wherein the cryopyrin-associated autoinflammatory syndrome is neonatal onset multisystem inflammatory disease.